Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.
Year: 2014
Type: article
Study design: Observational Study
Abstract: There is a lack of validated tools for assessing Alzheimer's disease (AD) across Asia. This study evaluates the psychometric properties of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian participants. Participants with mild to moderate AD (n=251) and healthy controls (n=51) from Mainland China, Taiwan, Singapore, Hong Kong, and South Korea completed selected instruments at several time points. Test-retest reliability was better than 0.70 for all tests. AD participants performed significantly more poorly than controls on every score. Within the AD group, greater disease severity corresponded to significantly poorer performance. The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time. The ADAS-Cog, DAD, and NTB are reliable, valid, and responsive measures in this population and could be used for clinical trials across Asian countries/regions.
Source: Europe PMC (PubMed Central)
Institutions: Pfizer (United States), Northwestern University, Peking Union Medical College Hospital, Peking University, Asan Medical Center, University of Ulsan, National University of Singapore, Chinese University of Hong Kong, Prince of Wales Hospital, Taipei Veterans General Hospital, National Yang Ming University, Seoul National University, Imperial College London, Cleveland Clinic, Lou Ruvo Brain Institute
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2151971979
